老年AML首次完全缓解后异基因移植获益的十年真实世界分析
法国FILO团队对60-70岁首次完全缓解的AML患者进行10年真实世界分析,采用三种时间依赖模型评估异基因移植获益。
要点
- 60-70岁AML首次完全缓解后移植显著改善RFS和OS,独立于ELN风险分组。
- 不移植者5年持续完全缓解概率极低(中危8%、高危1%)。
- 超标志点模型验证移植改善RFS(HR 0.47)和OS(HR 0.54)。
核心结论
- 首次完全缓解期异基因移植显著改善适合的老年AML患者结局。
- 不移植者长期无复发生存率极低(<10%),支持移植作为最佳治愈选择。
研究设计与样本
- 法国FILO开展的10年真实世界时间依赖分析。
- 纳入60-70岁经强化化疗后首次完全缓解的AML患者,按ELN 2010分为中危或高危。
- 采用三种模型分析:时间依赖Cox、多状态动态预测、超标志点模型。
主要发现
- 多状态模型预测5年持续完全缓解概率:中危不移植8%,高危不移植1%。
- 动态预测证实不移植患者随时间持续复发。
临床怎么用
- 对60-70岁适合的AML首次完全缓解患者,应考虑异基因移植以改善生存。
- 不移植者长期无复发生存极低,需与患者充分沟通移植的治愈潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The benefit of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with acute myeloid leukemia (AML) aged >60 years remains a matter of debate, notably when performed in first complete remission (CR1). To clarify this issue, the French Innovative Leukemia Organization (FILO) performed a 10-year real-world time-dependent analysis. The study enrolled patients between 60 and 70 years of age with AML in CR1 after intensive chemotherapy with intermediate (IR) or unfavorable (UR) risk according to the European LeukemiaNet (ELN) 2010 classification. The impact of allo-HSCT was analyzed through three models: (1) time-dependent Cox; (2) multistate for dynamic prediction; and (3) super landmark. The study enrolled 369 (73%) IR and 138 (27%) UR patients with AML, 203 of whom received an allo-HSCT. Classical multivariate analysis showed that allo-HSCT significantly improved relapse-free survival (RFS; hazard ratio [HR] [95% confidence interval (CI)], 0.47 [0.35-0.62]; P < .001) and overall survival (OS; HR [95% CI], 0.56 [0.42-0.76]; P < .001), independently of the ELN risk group. With the multistate model, the predicted 5-year probability for IR and UR patients to remain in CR1 without allo-HSCT was 8% and 1%, respectively. Dynamic predictions confirmed that patients without allo-HSCT continue to relapse over time. Finally, the super landmark model showed that allo-HSCT significantly improved RFS (HR [95% CI], 0.47 [0.36-0.62]; P < .001) and OS (HR [95% CI], 0.54 [0.40-0.72]; P < .001). allo-HSCT in CR1 is reported here as significantly improving the outcome of fit older patients with AML. Long-term RFS without allo-HSCT is very low (<10%), supporting allo-HSCT as being the best curative option for these patients.
引用
- Devillier R, Forcade E, Garnier A, et al. In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study. Blood Adv. 2022. PMID: 34525180. doi:10.1182/bloodadvances.2021004435
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。